| http://dbpedia.org/ontology/abstract
|
A vascular-targeting agent (VTA) or vascul … A vascular-targeting agent (VTA) or vascular disrupting agent (VDA) is a drug designed to damage the vasculature (blood vessels) of cancer tumors causing central necrosis. VTAs can be small-molecule or ligand-based. Small-molecule VTAs include:
* microtubule destabilizing drugs such as combretastatin A-4 disodium phosphate (CA4P), ZD6126, AVE8062, Oxi 4503
* vadimezan (ASA404)6, AVE8062, Oxi 4503
* vadimezan (ASA404)
|
| http://dbpedia.org/ontology/wikiPageID
|
20689225
|
| http://dbpedia.org/ontology/wikiPageLength
|
1775
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1098847296
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Plinabulin +
, http://dbpedia.org/resource/Combretastatin_A-4_disodium_phosphate +
, http://dbpedia.org/resource/Tumor +
, http://dbpedia.org/resource/Cancer +
, http://dbpedia.org/resource/ZD6126 +
, http://dbpedia.org/resource/Vadimezan +
, http://dbpedia.org/resource/Blood_vessel +
, http://dbpedia.org/resource/Ligand_%28biochemistry%29 +
, http://dbpedia.org/resource/Category:Cancer_treatments +
, http://dbpedia.org/resource/Category:Drugs_acting_on_the_cardiovascular_system +
, http://dbpedia.org/resource/Microtubule +
, http://dbpedia.org/resource/AVE8062 +
, http://dbpedia.org/resource/Necrosis +
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Antineoplastic-drug-stub +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Cancer_treatments +
, http://dbpedia.org/resource/Category:Drugs_acting_on_the_cardiovascular_system +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Drug +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Vascular-targeting_agent?oldid=1098847296&ns=0 +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Vascular-targeting_agent +
|
| owl:sameAs |
http://dbpedia.org/resource/Vascular-targeting_agent +
, http://rdf.freebase.com/ns/m.0520hfr +
, http://yago-knowledge.org/resource/Vascular-targeting_agent +
, http://www.wikidata.org/entity/Q7916442 +
, https://global.dbpedia.org/id/4xXmH +
|
| rdf:type |
http://dbpedia.org/class/yago/Substance100020090 +
, http://dbpedia.org/class/yago/Drug103247620 +
, http://dbpedia.org/class/yago/Agent114778436 +
, http://dbpedia.org/class/yago/CausalAgent100007347 +
, http://dbpedia.org/ontology/Drug +
, http://dbpedia.org/class/yago/PhysicalEntity100001930 +
, http://dbpedia.org/class/yago/Matter100020827 +
, http://dbpedia.org/class/yago/CytotoxicDrug103157987 +
, http://dbpedia.org/class/yago/WikicatExperimentalCancerDrugs +
, http://dbpedia.org/class/yago/Antineoplastic102722458 +
, http://dbpedia.org/class/yago/Medicine103740161 +
|
| rdfs:comment |
A vascular-targeting agent (VTA) or vascul … A vascular-targeting agent (VTA) or vascular disrupting agent (VDA) is a drug designed to damage the vasculature (blood vessels) of cancer tumors causing central necrosis. VTAs can be small-molecule or ligand-based. Small-molecule VTAs include:
* microtubule destabilizing drugs such as combretastatin A-4 disodium phosphate (CA4P), ZD6126, AVE8062, Oxi 4503
* vadimezan (ASA404)6, AVE8062, Oxi 4503
* vadimezan (ASA404)
|
| rdfs:label |
Vascular-targeting agent
|
